The popularity of glucagon-like peptide-1 receptor (GLP-1R) drugs has exploded in recent years due to their abilities in effectively treating metabolic-related disorders such as obesity and type 2 diabetes. As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase fourfold to an estimated $142 billion by 2030.
Novo Nordisk and Eli Lilly are poised to dominate the market, collectively capturing 94% of the total 2030 GLP-1R sales, which places them far ahead of any and all competitors in this category, says GlobalData, a leading data and analytics company.
According to GlobalData, the 11 approved drugs in the GLP-1R category generated $37.2 billion in 2023, cementing their place as one of the most lucrative therapies.
Jasper Morley, Pharma Analyst at GlobalData, comments: “Novo Nordisk and Eli Lilly accounted for nine of the approved GLP-1R products in 2023 and encompassed 99% of the sales. Successful GLP-1R products in 2023 included Novo Nordisk’s Ozempic and Wegovy, which generated $13.9 billion and $4.6 billion, respectively, as well as Eli Lilly’s Trulicity and Mounjaro, which generated $7.1 billion and $5.1 billion.”
GLP-1R market: A two horse race, GlobalData
The popularity of glucagon-like peptide-1 receptor (GLP-1R) drugs has exploded in recent years due to their abilities in effectively treating metabolic-related disorders such as obesity and type 2 diabetes. As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase fourfold to an estimated $142 billion by 2030.
Novo Nordisk and Eli Lilly are poised to dominate the market, collectively capturing 94% of the total 2030 GLP-1R sales, which places them far ahead of any and all competitors in this category, says GlobalData, a leading data and analytics company.
According to GlobalData, the 11 approved drugs in the GLP-1R category generated $37.2 billion in 2023, cementing their place as one of the most lucrative therapies.
Jasper Morley, Pharma Analyst at GlobalData, comments: “Novo Nordisk and Eli Lilly accounted for nine of the approved GLP-1R products in 2023 and encompassed 99% of the sales. Successful GLP-1R products in 2023 included Novo Nordisk’s Ozempic and Wegovy, which generated $13.9 billion and $4.6 billion, respectively, as well as Eli Lilly’s Trulicity and Mounjaro, which generated $7.1 billion and $5.1 billion.”
